Viking Therapeutics (NASDAQ:VKTX) had its price target lowered by investment analysts Raymond James from $13.00 to $10.00 in a note issued to investors on Thursday, Analyst Price Targets reports. The company currently has an “outperform” rating on shares of the biotech company. Raymond James’ target price indicates upside potential of 168.10% from the current share price.
A number of other research analysts have also weighed in on VKTX recently. Zacks Investment Research upgraded Viking Therapeutics from a “buy” to a “hold” rating in a Friday, January 7 research report. Maxim Group launched a hedge on Viking Therapeutics shares in a research note on Friday, November 12. They issued a “buy” rating and a price target of $14.00 for the company. BMO Capital Markets reissued a “buy” rating and posted a $15.00 price target on Viking Therapeutics shares in a research note on Monday, November 8. William Blair reaffirmed a “buy” rating on Viking Therapeutics shares in a Friday, October 29 research report. Finally, SVB Leerink reiterated an “outperforming” rating on Viking Therapeutics shares in a Wednesday, November 3 research report. One investment analyst gave the stock a hold rating and seven gave the company a buy rating. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $14.21.
NASDAQ: VKTX opened at $3.73 on Thursday. The company has a market capitalization of $291.82 million, a price-earnings ratio of -5.25 and a beta of 1.63. Viking Therapeutics has a 1-year low of $3.21 and a 1-year high of $9.41. The company has a fifty-day moving average price of $4.37 and a 200-day moving average price of $5.49.
Viking Therapeutics (NASDAQ:VKTX) last released quarterly earnings data on Wednesday, February 9. The biotech company reported ($0.16) earnings per share for the quarter, beating the Zacks consensus estimate of ($0.19) by $0.03. During the same period of the previous year, the company achieved EPS of ($0.15). Research analysts expect Viking Therapeutics to post -0.74 earnings per share for the current year.
A number of large investors have changed their holdings in VKTX recently. ArrowMark Colorado Holdings LLC increased its position in Viking Therapeutics by 4.2% in Q3. ArrowMark Colorado Holdings LLC now owns 7,993,211 shares of the biotech company worth $50,197,000 after purchasing an additional 322,659 shares during the period. Vanguard Group Inc. increased its stake in shares of Viking Therapeutics by 1.1% during the second quarter. Vanguard Group Inc. now owns 3,280,810 shares of the biotech company valued at $19,653,000 after buying 34,619 additional shares in the last quarter. Geode Capital Management LLC increased its holdings of Viking Therapeutics shares by 2.3% in the third quarter. Geode Capital Management LLC now owns 1,187,322 shares of the biotech company worth $7,456,000 after purchasing an additional 26,997 shares during the period. Dimensional Fund Advisors LP increased its stake in Viking Therapeutics shares by 38.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,063,108 shares of the biotech company worth $4,890,000 after acquiring 296,385 additional shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in Viking Therapeutics by 5.8% in the third quarter. Two Sigma Investments LP now owns 876,324 shares of the biotech company worth $5,503,000 after purchasing an additional 48,380 shares during the period. Institutional investors hold 48.27% of the company’s shares.
About Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, engaged in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The Company’s VK5211 clinical program treats patients recovering from non-elective hip fracture surgery. It is also specialized in the development of VK2809 and VK0214.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Viking Therapeutics right now?
Before you consider Viking Therapeutics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Viking Therapeutics wasn’t on the list.
Although Viking Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here